Scalper1 News
The IBD 50 is a ranking of leading stocks based on key fundamental and technical measures including earnings and sales growth, profit margins, return on equity and relative price performance. Here’s a closer look at four drug stocks that made the new list Friday: Regeneron Pharmaceuticals (REGN), Valeant Pharmaceuticals (VRX), Actavis (ACT) and Gilead Sciences (GILD). Regeneron has a highest possible IBD Composite Rating of 99. On Friday, the FDA Scalper1 News
Scalper1 News